Celosia Therapeutics key facts
- Developer of neurotherapeutic interventions designed for treatment-resistant neurodegenerative conditions.
- It has raised $18.8M.
- Notable investors include UniSuper Superannuation Fund, Iomar Barrett, Macquarie University Incubator, Uniseed.
- Status: Privately Held (backing).
Who backs Celosia Therapeutics
4- ·Watch Celosia Therapeutics: the Monday email on marks, rounds and moves
Celosia Therapeutics funding rounds
No funding rounds for Celosia Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Celosia Therapeutics investors
4 investors are on record for Celosia Therapeutics, including UniSuper Superannuation Fund, Iomar Barrett, Macquarie University Incubator and Uniseed.
About Celosia Therapeutics
Developer of neurotherapeutic interventions designed for treatment-resistant neurodegenerative conditions. The company modifies the neuronal microenvironment through targeted molecular approaches, focusing on diseases such as ALS, Alzheimer's, frontotemporal dementia, and Dravet syndrome, and incorporates translational research, disease-specific biomarkers, and preclinical validation strategies, enabling neuroscience researchers and clinical developers to explore novel therapeutic pathways for disorders with limited or no existing treatment options.
- Sector
- Healthcare
- HQ
- Macquarie Park, Australia
- Founded
- 2022
- Employees
- 4
- Website
- celosiatx.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
Celosia Therapeutics doesn't have a valuation on record yet — one is published once a priced round, a reported valuation, fund marks, or secondary prints surface in our sources. The rest of the record below builds toward it.